LAG3 and melanoma: Cell death was not decreased in the presence of either sLAG-3, anti-MHC-II antibody or a combination of sLAG-3 and anti-MHC-II in both untreated and IFN-γ-treated cells, indicating that unlike previously reported in melanoma, engagement of MHC-II on PDAC cells does not confer protection against Fas-mediated cell death.